These findings delineate a novel pathogenic mechanism in NPC, highlighting the KLF1/CLPTM1L/ERLIN2/SREBP1 regulatory cascade as a promising therapeutic target for NPC treatment. The gene discussed is CLPTM1L; the disease is nasopharyngeal carcinoma.